CathWorks’ FFRangio Compared With Invasive Pressure Wire-Guided PCI in Medicare Outcomes Data Through 2 Years

March 9, 2026—CathWorks announced the presentation of outcomes data from a cohort of more than 4,000 Medicare patients demonstrating that angiography-derived physiology (ADP) using CathWorks FFRangio resulted in similar clinical outcomes compared with invasive pressure wire-guided percutaneous coronary intervention (PCI) through 2 years. Additionally, the data highlight the rapidly growing adoption of ADP in the United States, noted the company.

According to the company, Medicare data from 2019 to 2024 were used to identify inpatient and outpatient physiological assessments performed with ADP or invasive pressure wire. ADP was propensity matched 1:3 to invasive pressure wire in patients who underwent PCI and separately in those who did not undergo PCI.

The primary outcome was the cumulative incidence through 2 years of major adverse cardiac events (MACE, defined as death, myocardial infarction [MI], or repeat revascularization). Secondary outcomes included each component of MACE, 30-day acute kidney injury, and major bleeding. The investigators calculated cost ratios for repeat revascularization and hospital readmissions through 1 year.

As reported in CathWorks press release, the findings included the following:

• In the PCI group of 1,591 ADP and 4,773 invasive pressure wire matched patients, the cumulative incidence of MACE was comparable through 2 years (24.8% vs 23.5%; hazard ratio [HR], 1.01; 95% CI, 0.85-1.20).
• In the non-PCI group of 2,532 ADP and 7,596 invasive pressure wire matched patients, the cumulative incidence of MACE was also comparable through 2 years (24.1% vs 23.9%; HR, 0.97; 95% CI, 0.84-1.11).

Among 466,535 invasive physiology assessments, ADP utilization grew approximately eightfold between 2019 and 2024, noted the press release.

The findings were presented as a late-breaking clinical trial at CRT 2026, the Cardiovascular Research Technologies conference, by Christopher Chieh Yang Koo, MBBS, from National University Hospital Singapore. The data were simultaneously published in Circulation: Cardiovascular Interventions by Dr. Koo et al on behalf of investigators from Smith Center for Outcomes Research in Cardiology at Harvard Medical School in Boston, Massachusetts.

The study's corresponding investigator Eric A. Secemsky, MD, of the Smith Center and the Director of Vascular Intervention at Beth Israel Deaconess Medical Center in Boston, commented on the findings in the company’s press release.

“This first look at contemporary data of the growing adoption of ADP in the United States shows similar clinical outcomes including death, MI, and revascularization through 2 years when compared with invasive pressure wires,” stated Dr. Secemsky. “When considering the promising secondary outcomes such as resource utilization advantages and the growing clinical body of evidence, specifically for CathWorks FFRangio, we expect the current trend of adoption for ADP to continue to grow at an even faster rate.”